Imidex has announced with pride that they appoint Wes Bolsen as their new Chief Executive Officer (CEO). Imidex co-founder Richard Vlasimsky will assume the role of Chief Technology Officer (CTO) as part of Bolsen's appointment. With a mission to revolutionize healthcare by detecting lung cancer in its earliest stages, Imidex will benefit from Bolsen's expertise, a serial entrepreneur who has helped secure over $500 million in venture capital and non-dilutive financing for his previous ventures, to evaluate strategic opportunities.
Wes Bolsen has a proven track record in commercializing breakthrough technologies across multiple industries and driving innovative companies to acquisition by industry-leading firms. With over two decades of experience in executive roles, Bolsen has led transformative initiatives to reshape industries and save lives.
"I am honored to join Imidex at this crucial moment," says Wes Bolsen, CEO of Imidex. "Lung cancer remains the deadliest form of cancer globally, but with Imidex's groundbreaking VisiRad™ XR detection program, we have the opportunity to detect lung cancer earlier. This technology will not only save lives but also billions of dollars in payer costs annually. Healthcare providers will also see billions of dollars in increased revenue through additional findings of lung nodules, which could increase the number of lung cancer patients treated in the USA by 50%."
IMDIEX's co-founder Richard Vlasimsky reflects on the company's journey and its potential to revolutionize the fight against lung cancer.
"With an immense team, advisors including cancer screening pioneer Stan Lapidus, and alongside company directors like Dax Craig, we have built a company that will make a meaningful difference in the fight against lung cancer," says co-founder Richard Vlasimsky. "Now, with Wes Bolsen leading as our CEO, we can commercialize this technology and place it in the hands of the right strategic partner."
Source: IMIDEX Press Release